

Isolation Of Extensively Drug Resistant Salmonella Typhi In Blood Culture From Tertiary Care University Hospital

Binish Arif Sultan

(Assistant Professor Pathology Jinnah Sindh Medical University)
Email: Binish.arif@jsmu.edu.pk

Suresh K Langhani

(Assistant Professor Pathology Jinnah Sindh Medical University)
Suresh.kumar@jsmu.edu.pk

Irum Shahzaib

(Senior lab technologist, JSMU laboratory)
email: rabita_28@yahoo.com

Zareen Irshad

(Assistant Professor Pathology Jinnah Sindh Medical University) zareen.irshad@jsmu.edu.pk

Salma Perveen

(Lecturer JSMU) salma.reween@jsmu.edu.pk

Sehrish Tariq

(lab technologist, JSMU laboratory)
email:sehrishtariq206@gmail.com

Background:

Typhoid fever is a serious systemic infection which affects all age group from children to elderly. It has multiple systemic effects as untreated infections may cause prolonged morbidity and hospitalization. The treatment modalities range multiple antibiotics like co-trimoxazole, ciprofloxacin, chloramphenicol and ampicillin. The treatment of choice in multidrug resistant *Salmonella* has been third generation cephalosporins like Ceftriaxone.

Methodology

Study design:

This cross sectional study was conducted in Jinnah Sindh Medical University laboratory Karachi.

Study duration: The total number of Blood culture received was 464 from January 1st to December 31 2019.

Results:

The total number of Blood culture received was 464, collected from January to December in year 2019 at Jinnah Sindh Medical University laboratory. The sample was received in BACTEC blood culture bottle. When a culture bottle signaled positive, the bottle was removed and an aliquot of the broth was Gram stain and processed for culture for organism identification and antimicrobial susceptibility testing During 2019 from January till December 464 blood cultures came to JSMU Diagnostic laboratory and blood bank out of which 31 cases of enteric fever were diagnosed in automated blood culture Bactec. All the isolated *Salmonella* belonged to *Salmonella typhi* subgroup and there was no case of salmonella paratyphi A or B. out of 31, 25 *Salmonella typhi* were resistant to Ceftriaxone sensitive only to azithromycin and

Meropenem. All the 31 positive XDR *Salmonella* cases were from patient of pediatric age group with range of 11 months to 14 years.

Conclusion:

The rise of extensively drug resistant *Salmonella* is alarming and leaves limited treatment options with carbapenems which are costly as well as require administration by injectable route. Preventive measures like improved sanitation and vaccination may be adapted in order to curtail spread of such resistant strains of typhoid.

Key Words: XDR *Salmonella typhi*, extremely drug resistant enteric fever

Background:

In the developing countries the burden of enteric fever is one of the many problematic infectious diseases that hampers development of healthy communities. In 2020, about 2 million people were diagnosed to suffer from this preventable infection worldwide. In 2020, typhoid fever caused over 200,000 deaths worldwide. Asia comprised a major chunk of these infections due to poor food and water availability of healthy food and potable water. (1). According to estimated figures of studies, despite advancement in this modern era, typhoid fever is still very common in developing countries accounting for an estimated 130 million infections and 800,000 deaths per year occurring worldwide (2).improvements in drinking water quality and proper sanitation comprises of plausible solutions to this avoidable spread of infectious disease. The advent of new conjugated vaccine in high-risk areas is a possible control strategy advised by the World Health Organization (WHO) for the short-to medium-term management of high risk group (3).The advent of new vaccine for typhoid and its application in school

children throughout the city is promising and hopefully can bring down the incidence of typhoid in this age group.

Typhoid has been historically treated by antibiotics like ampicillin, trimethoprim-sulfamethoxazole, and chloramphenicol; hence these are termed as first line treatment antibiotics (4). Those strains of Salmonella typhi, which show resistance to these three antibiotics, are considered multidrug resistant (MDR), and resistant isolates were first observed in the late 1970s to early 1980s. These resistant strains were treated with fluoroquinolones (ciprofloxacin, ofloxacin) which constitute the second line treatment. Non-susceptibility to the second-line antibiotics (the fluoroquinolones) or fluoroquinolones resistance has also been frequently reported since these became the treatment of choice in regions with MDR infections. Ceftriaxone, a third-generation injectable cephalosporin, and azithromycin, a macrolide, are employed as the treatment for typhoid fever when other options cannot be used as typhoid strains show resistance to first and second line antibiotics (4). However, periodic cases of ceftriaxone- or azithromycin resistant typhoidal salmonella infection have recently been reported. Over the last twenty years, a dominant, commonly MDR, haplotype of S. Typhi called H58 has been disseminating all over the world (5). It is rampant across South and Southeast Asia. Several local outbreaks of typhoid have been linked to the new circulating XDR clone (6-8).

Fluoroquinolones like ciprofloxacin are considered treatment of choice in treating typhoid fever caused by multidrug resistant strains of Salmonella typhi but with increasing antibiotic resistance there are numerous reports of treatment failures with fluoroquinolones (9). Multidrug resistance (MDR), defined as resistance to the three first-line classes of antimicrobial agents (chloramphenicol, ampicillin, and trimethoprim/sulfamethoxazole [TMP/SMX]), has become prevalent in most of South Asia, with figures reaching 15% in India and 45% in Pakistan (10). There has been previous research in Pakistan demonstrating increase in resistance against Ciprofloxacin. The trend of antibiotic resistance was already on the rise with emerging MDR strains of salmonella (11). Extensively drug resistant salmonella is defined as in addition to being Multi drug resistant isolates are resistant to third generation cephalosporins (cefixime / ceftriaxone). Previously reports of emerging resistance in Salmonella typhi and paratyphi against third generation cephalosporins which is termed as XDR strains was seen first reported by outbreak in Hyderabad Sindh. Subsequently it was sporadically reported by cases seen in Karachi followed by widespread uprising of reported cases of XDR Salmonella typhi.

Materials and methods:

Study design:

This cross sectional study was conducted in Jinnah Sindh Medical University laboratory Karachi.

Study duration: The total number of Blood culture received was 464 from January 1st to December 31 2019.

Methodology:

Ethical permission to use lab data was taken from JSMU laboratory as no patient confidential data was used and privacy was maintained. The samples were received in BACTEC blood culture bottle. When a Bactec bottle gave a positive fluorescent signal, it was removed and an aliquot of the broth was Gram Stained and processed by sub culturing on blood agar and Mac conkey agar, antibiotic sensitivity was done on Mueller Hinton agar (MHA). After 24 hours of incubation, the grown bacterial colonies were identified by serological identification, done by Remel 9-0 antisera and biochemical identification was done by TSI, urea, SIM and citrate. Antibiotic sensitivity done on MHA was interpreted using CLSI 2018 break points for Salmonella.

Results:

During 2019 from January till December 464 blood cultures came to JSMU Diagnostic laboratory and blood bank out of which 31 cases of enteric fever were diagnosed in automated blood culture Bactec 9050. All the isolated Salmonella belonged to Salmonella typhi subgroup. Out of 31 isolates 26 Salmonella were resistant to Ampicillin, chloramphenicol, co- trimoxazole, Cefixime and Ceftriaxone, with showing sensitivities only to azithromycin and meropenem. The antibiotic susceptibility of the xdr isolates showed, all but five were resistant to ampicillin, chloramphenicol, co-trimoxazole and third generation cephalosporin (cefixime and ceftriaxone). Remaining five Salmonella were resistant to cefixime but sensitive to ceftriaxone. None of the isolates were resistant to azithromycin, meropenem and imipenem.

The age group of all patients with salmonella infection ranged from 6 months to 14 years. Out of thirty one cases, 18 were male and 12 were female.

All but five patients with XDR Salmonella were treated with azithromycin for 5 days with complete recovery on follow up. The remaining five pediatric patients were treated with meropenem as they were clinical unstable to be treated with oral antibiotics.

However, vaccination could not immediately be undertaken to prevent the spread of this highly resistant clone to patients and their household contacts due to unavailability free of cost vaccine and inability of these poor patients with limited resources to afford it privately. Patients' families were counseled to increase awareness about ease of spread among house hold contacts and preventive measures like hand washing, boiling drinking water, consumption of hygienic food and drinks. Handouts about awareness of proper sanitation and proper disposal of human wastes was also given to patients' attendants in order

to drive knowledge and attention to take steps to break the chain of transmission of these infections.

Discussion:

Typhoid fever is a life-threatening infectious disease caused by *Salmonella enterica* serovar Typhi. *Salmonella typhi* is a strict human pathogen and colonizes only humans, is transmitted through the fecal-oral route. Typhoid fever can be managed invariably by adequate and timely antimicrobial treatment. The emergence and spread of extremely drug resistant *Salmonella* is distressing and leaves limited treatment options with carbapenems which are costly as well as require administration by injectable. Preventive measures like improved potable water quality sanitation and vaccination in high-risk areas are means of potential control strategy recommended by the World Health Organization (WHO) for the short-to medium-term management.

Typhoid fever is a notifiable illness in the Sindh province of Pakistan. The cases of *Salmonella typhi* and paratyphi identified in blood are reported to the Sindh health authorities with a special note to indicate the emergence of ceftriaxone resistance. Swift emergence and brisk spread of resistant isolates underline the significance of AMR surveillance for typhoid and other enteric Gram-negative bacteria and draw attention to the inadequacy of relying solely on non-culture-based serological methods for diagnosis of typhoid (such as Widal and Typhidot tests), which do not provide susceptibility results. In view of the emergence of ceftriaxone resistance in *Salmonella typhi*, culture- and sensitivity-guided treatment becomes crucial as empirical treatment with ceftriaxone is no longer dependable in the region. (12) Following antibiotic resistance testing, cases were effectively treated with azithromycin and meropenem, resulting in recovery by all patients. Immediate control measures include education of the patients and household members and emphasis on hygiene and food safety.

The appearance and stretch of XDR *S. Typhi* in Sindh, Pakistan, is a disquieting revelation of how an omnipresent antibiotic resistance can be acquired by MDR *S. Typhi*, rendering it XDR and further thinning management options. Antibiotics save millions of lives annually, but the evident ease and rapidity by which life-threatening bacteria such as *S. Typhi* can develop resistance severely limit their efficacy.

Small data from tertiary care hospital university laboratory propose that better strategies against typhoid are warranted, such as awareness of treating clinicians to send blood cultures when suspecting enteric fever and not rely on serological typhoidal tests as they are not specific and cannot give information regarding antibiotic susceptibility pattern.

Limitations:

1. This study included only bacteremic isolates of XDR *Salmonella*. 21 of the patients were lost to

follow up after reporting of positive culture and treatment history could not be taken via telephonic communication and only advice for treatment was sent through a comment in the blood culture report.

2. The study participants who were hospitalized in JPMC and NICH provided relevant clinical history, but clinical details of 14 outpatients from various parts of Karachi could not be obtained.

Age group	ceftriaxone resistant	ceftriaxone sensitive	Male	Female
6month-14 years	26	--	16	10
1year-10years	--	05	3	2

Isolation of *Salmonella typhi* in different age group and gender

Table 1: Age group and resistance patterns of XDR *Salmonella*




Figure 1 Graphical distribution of 464 blood cultures (total blood cultures) during year 2019 from JSMU laboratory

References

- Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. *Bull World Health Organ.* 2004; 82: 346-53.
- Richard G Mather ,1,2 Heidi Hopkins ,2 Christopher M Parry ,3,4 Sabine Dittrich2. Redefining typhoid diagnosis: what would an improved test need to look like? *BMJ Global Health* 2019; 4:e001831. doi:10.1136/bmjgh-2019-001831
- Rahman BA, Wasfy MO, Maksoud MA, Hanna N, Dueger E, House B. Multi-drug resistance and reduced susceptibility to ciprofloxacin among *Salmonella enterica* serovar Typhi isolates from the Middle East and Central Asia. *New Microbes New Infect.* 2014; 2: 88-92. 4
- Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. *Bull World Health Organ.* 2008; 86: 260-8.
- Justin Im, Md. Taufiqul Islam, Faisal Ahmmed, Deok Ryun Kim, Ashrafal Islam Khan, Khalequ Zaman, Can Existing Improvements of Water, Sanitation, and Hygiene (WASH) in Urban Slums Reduce the Burden of Typhoid Fever in These Settings?
- Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM. 2015. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and

antimicrobial management of invasive salmonella infections. *Clin Microbiol Rev* 28:901–937.

7. Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, et al. D. 2015. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of *Salmonella* Typhi identifies inter- and intracontinental transmission events. *Nat Genet* 47:632– 639. <https://doi.org/10.1038/ng.3281>.

8. Feasey NA, Gaskell K, Wong V, Msefula C, Selemani G, Kumwenda S, Allain TJ, Mallewa J, Kennedy N, Bennett A, Nyirongo JO, Nyondo PA, Zulu MD, Parkhill J, Dougan G, Gordon MA, Heyderman RS. 2015. Rapid emergence of multidrug resistant, H58-lineage *Salmonella* typhi in Blantyre, Malawi. *PLoS Negl Trop Dis* 9:e0003748.

9. Hendriksen RS, Leekitcharoenphon P, Lukjancenko O, Lukwesa-Musyani C, Tambatamba B, Mwaba J, Kalonda A, Nakazwe R, Kwenda G, Jensen JD, Svendsen CA, Dittmann KK, Kaas RS, Cavaco LM, Aarestrup FM, Hasman H, Mwansa JC. 2015. Genomic signature of multidrug-resistant *Salmonella* enterica serovar typhi isolates related to a massive outbreak in Zambia between 2010 and 2012. *J Clin Microbiol* 53:262–272. <https://doi.org/10.1128/JCM.02026-14>.

10. Pham Thanh D, Thompson CN, Rabaa MA, Sona S, Sopheary S, Kumar V, Moore C, Tran Vu Thieu N, Wijedoru L, Holt KE, Wong V, Pickard D, Thwaites GE, Day N, Dougan G, Turner P, Parry CM, Baker S. 2016. The molecular and spatial epidemiology of typhoid fever in rural Cambodia. *PLoS Negl Trop Dis* 10:e0004785. <https://doi.org/10.1371/journal.pntd.0004785>.

11. Pham Thanh D, Karkey A, Dongol S, Ho Thi N, Thompson CN, Rabaa MA, Arjyal A, Holt KE, Wong V, Tran Vu Thieu N, Voong Vinh P, Ha Thanh T, Pradhan A, Shrestha SK, Gajurel D, Pickard D, Parry CM, Dougan G, Wolbers M, Dolecek C, Thwaites GE, Basnyat B, Baker S. 2016. A novel ciprofloxacin-resistant subclade of H58 *Salmonella* typhi is associated with fluoroquinolone treatment failure. *Elife* 5:e14003. <https://doi.org/10.7554/eLife.14003>

12. Medalla F, Sjolund-Karlsson M, Shin S, Harvey E, Joyce K, Theobald L, et al. Ciprofloxacin-resistant *Salmonella* enterica Serotype Typhi, United States, 1999-2008. *Emerg Infect Dis*. 2011; 17:1095-8.

13. Qamar FN, Azmatullah A, Kazi AM, Khan E, Zaidi AK. A three-year review of antimicrobial resistance of *Salmonella* enterica serovars Typhi and Paratyphi A in Pakistan. *J Infect Dev Ctries*. 2014; 8:981-6.

14. Klemm EJ, Shakoor S, Page AJ, Qamar FN, Hasan R et al. 2018. Emergence of an extensively drug resistant *Salmonella* enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. *mBio* 9:e00105-18.